Pharmacokinetics in Subjects With Renal Impairment
Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
This is an open-label, non-randomized, parallel-group, mono-center, single intravenous dose,
Phase I trial to investigate the Pharmacokinetic (PK) and safety of cilengitide in subjects
with different grades of renal impairment as compared to subjects with normal renal function.